Core Viewpoint - The report provides a detailed account of Wuhan Keqian Biological Co., Ltd.'s fundraising activities, including the total amount raised, usage of funds, and management practices, ensuring compliance with regulatory requirements [1][2][3][4][5] Fundraising Overview - The company raised a total of RMB 1,227.45 million through the issuance of 105 million shares at a price of RMB 11.69 per share, with net proceeds amounting to RMB 1,158.26 million after deducting underwriting fees [1] - As of December 31, 2024, the cumulative amount invested from the raised funds was RMB 854.01 million, leaving a balance of RMB 337.87 million [1][2] Fund Usage and Management - The company has established a dedicated account for managing the raised funds, adhering to the "Three-party Supervision Agreement" with the bank and sponsor to ensure proper usage [1][2] - As of June 30, 2025, the company had directly invested RMB 89.23 million into fundraising projects and incurred a total of RMB 5.20 million in handling fees [2][3] Cash Management - The company has utilized idle funds for cash management, achieving a total return of RMB 13.42 million from interest and investment income [1][3][5] - The total amount of idle funds managed was RMB 365 million, with a cash management balance of RMB 230 million as of June 30, 2025 [5] Project Changes - The company terminated the "Animal Biological Product Workshop Technical Renovation Project" and redirected the remaining funds of RMB 287.14 million to the "High-level Animal Vaccine Industrialization Base Construction Project (Phase I)" [4][5] - The decision to change the project was approved by the board and the supervisory committee, ensuring compliance with regulatory requirements [4][5] Fund Usage Reporting - The report includes detailed tables showing the usage of raised funds, with a total of RMB 94.32 million invested in various projects by the end of the reporting period [4][5] - The company has not encountered any issues in disclosing the usage of funds, maintaining transparency in accordance with regulatory guidelines [4]

证券代码：600757 证券简称：长江传媒 公告编号：临 2025-031 长江出版传媒股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证监会发布的《上市公司募集资金监管规则》和上海证券交易所发 布的《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关规定， 长江出版传媒股份有限公司（以下简称"公司"或"本公司"）董事会编制了截 至 2025 年 6 月 30 日止的《公司 2025 年半年度募集资金存放与实际使用情况 的专项报告》。 一、募集资金基本情况 （一）实际募集资金金额及资金到账时间 经中国证券监督管理委员会证监许可〔2013〕331 号文核准，由主承销商 国泰君安证券股份有限公司采用非公开发行方式，向特定对象非公开发行人民币 普通股（A 股）股票 173,965,824 股，发行价为每股人民币 6.73 元，共计募集 资金 117,079 万元，扣除承销和保荐费用 2,680 万元后的募集资金为 114,399 万元， ...

浙江菲达环保科技股份有限公司 专项报告 根据中国证券监督管理委员会《上市公司募集资金监管规则（2025 年 5 月 发布）》（证监会公告〔2025〕10 号）、《上海证券交易所上市公司自律监管指引 第 1 号—规范运作（2025 年 5 月修订）》以及《上海证券交易所上市公司自律监 管指南第 1 号—公告格式（2025 年 4 月修订）》的相关规定，浙江菲达环保科技 股份有限公司（以下简称公司）就 2025 年半年度募集资金存放、管理与实际使 用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准浙江菲达环保科技股份有限公司向 杭州钢铁集团有限公司发行股份购买资产并募集配套资金的批复》（证监许可 〔2022〕810 号），本公司由主承销商中信证券股份有限公司采用非公开发行方 式，于 2022 年 8 月 17 日向特定对象发行人民币普通股（A 股）股票 16,422.14 万股，发行价为每股人民币 4.86 元，共计募集资金 79,811.60 万元，扣除发行费 用 519.27 万元（不含税）后，公司本次募集资金净额为 79,292.33 万 ...

浙江亨通控股股份有限公司 募集资金使用管理办法 第一章 总则 第一条 为规范浙江亨通控股股份有限公司（以下简称"公司"）募集资金 的管理和使用，保护投资者利益，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司证券发行管理办法》《上海证券交易所股票上市规则》 （以下简称"《股票上市规则》"）、《上市公司募集资金监管规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》等法律法规、规范性文件 以及《浙江亨通控股股份有限公司章程》（以下简称"《公司章程》"）的规定， 并结合公司实际情况，特制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金监管，但不包括公司实施股权激励 计划募集的资金监管。 公司董事会应当对募集资金投资项目（以下简称"募投项目"）的可行性进 行充分论证，确信投资项目具有较好的市场前景和盈利能力，有效防范投资风险， 提高募集资金使用效益。 第三条 公司对募集资金的管理遵循专户存放、专款专用、严格管理、如实 披露的原则。公司董事会负责建立并完善募集资金存储、使用和管理的内部控制 制度，对募集资金存储、使 ...

Core Points - The report details the fundraising activities and usage of funds by Guangdong Jiayuan Technology Co., Ltd, including the issuance of convertible bonds and A-shares, along with the management of raised funds [1][2][3] Fundraising Overview - The company raised a total of RMB 1,225.16 million from the issuance of 12.4 million convertible bonds, with net proceeds after expenses amounting to RMB 1,225.16 million [1] - Additionally, the company raised RMB 3,378.39 million from the issuance of 70,257,493 A-shares, with net proceeds of RMB 3,378.39 million after deducting issuance costs [1][2] Fund Usage and Balance - As of June 30, 2025, the company had used RMB 1,157.41 million of the raised funds, with a remaining balance of RMB 113.00 million, including interest income [1][3] - The company reported interest income from raised funds totaling RMB 22.80 million, with no income from financial products in the first half of 2025 [1][3] Fund Management - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, enhancing the efficiency and effectiveness of fund usage [1][2] - The company has signed tripartite supervision agreements with various banks to manage the raised funds securely [2] Project Investment Status - The company has invested in several projects, including a high-performance copper foil project and a technology innovation center, with varying degrees of completion and effectiveness [4][5] - The company has adjusted the internal investment structure of certain projects, extending the expected completion date for some projects due to market conditions and operational challenges [5][7] Financial Management of Idle Funds - The company has utilized idle funds for cash management, investing in low-risk financial products, with a balance of RMB 230.56 million in the cash management account as of June 30, 2025 [6][7] - No idle funds were used to temporarily supplement working capital during the reporting period [6][7] Summary of Fund Usage - The total amount of funds raised and their usage is detailed in specific tables, showing the allocation and progress of various projects [4][5] - The company has not encountered significant issues regarding the use and disclosure of raised funds during the reporting period [5][8]

浙江双元科技股份有限公司 募集资金管理制度 浙江双元科技股份有限公司 第一章 总则 第六条 公司的控股股东、实际控制人及其他关联人不得占用公司募集资金，不 得利用公司募集资金投资项目（以下简称"募投项目"）获取不正当利益。 公司发现控股股东、实际控制人及其他关联人占用募集资金的，应当及时要求归 还，并披露占用发生的原因、对公司的影响、清偿整改方案及整改进展情况。 浙江双元科技股份有限公司 募集资金管理制度 第七条 保荐人或者独立财务顾问应当按照《证券发行上市保荐业务管理办法》 《科创板上市规则》、本制度的规定，对科创公司募集资金的管理和使用履行持续督 导职责。 第二章 募集资金存储 第八条 公司应当将募集资金存放于经董事会批准设立的专项账户（以下简称 "募集资金专户"）集中管理和使用。 第一条 为规范浙江双元科技股份有限公司（以下简称"公司"）募集资金的管 理和使用，保护投资者的权益，根据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》（以 下简称"《科创板上市规则》"）《上海证券交易所科创板上市公司自律监管指引第 章程》（以下简称"《公司章程 ...

Core Points - The article discusses the approval and verification of Zhejiang Shuangyuan Technology Co., Ltd.'s use of its own foreign exchange to pay for investment projects and subsequently replace it with raised funds [1][4][6] Group 1: Fundraising Overview - The company was approved to publicly issue 14.7857 million shares at a price of RMB 125.88 per share, raising a total of RMB 1,861.22 million, with a net amount of RMB 1,666.36 million after deducting issuance costs [1][2] - The funds raised will be allocated to various investment projects, with a planned usage of RMB 651.58 million and excess funds of RMB 1,014.78 million [2][3] Group 2: Investment Project Details - The investment projects include the Intelligent Measurement and Control Equipment Production Base, R&D Center, Marketing Network and Technical Support Center, and working capital supplementation [2][3] - As of June 30, 2025, the total investment in these projects is expected to reach RMB 711.31 million [3] Group 3: Use of Own Foreign Exchange - The company plans to use its own foreign exchange for payments related to overseas procurement during the implementation of investment projects, aiming to enhance the efficiency of fund usage [4][5] - The process involves prior approval for payments, followed by a replacement of the amount with raised funds from the dedicated account [4][5] Group 4: Impact and Approval Process - This approach is expected to improve overall operational efficiency and is deemed beneficial for the company and its shareholders [5][6] - The board and supervisory committee have approved the plan, confirming that it does not alter the intended use of raised funds or harm shareholder interests [5][6][7]

Meeting Overview - The third meeting of the Supervisory Board of Suzhou Tianlu Technology Co., Ltd. was held on August 25, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws, regulations, and the company's articles of association [1] Financial Report Review - The Supervisory Board reviewed the 2025 semi-annual report and its summary, concluding that they accurately reflect the company's operational status for the first half of 2025 without any false records or omissions [1][2] - The voting result for the report was unanimous, with 3 votes in favor and no opposition or abstentions [2] Fund Usage Report - The Supervisory Board approved the special report on the storage and usage of raised funds for the first half of 2025, confirming its accuracy and compliance with regulations [2] - The voting result for the fund usage report was also unanimous, with 3 votes in favor [2] Asset Impairment Provision - The Supervisory Board agreed that the provision for asset impairment was in line with relevant guidelines and accurately reflects the company's financial status [2][3] - The voting result for the asset impairment provision was unanimous, with 3 votes in favor [3] Non-operating Fund Occupation - The Supervisory Board confirmed that there were no non-operating fund occupations by controlling shareholders or related parties as of June 30, 2025 [3] - The voting result for this review was unanimous, with 3 votes in favor [3] Cash Management of Idle Funds - The Supervisory Board approved the use of part of the idle raised funds for cash management, stating it would enhance fund efficiency without harming the interests of the company or its shareholders [3] - The voting result for the cash management decision was unanimous, with 3 votes in favor [3]

Core Viewpoint - Shanghai Sailun Biotechnology Co., Ltd. has reported on the management and usage of raised funds for the first half of 2025, detailing the total amount raised, expenditures, and remaining balances in compliance with regulatory requirements [1][2]. Fundraising Overview - The company raised a total of RMB 89,379.18 million by issuing 27.06 million shares at a price of RMB 33.03 per share, with all funds received by March 4, 2022 [1]. - As of June 30, 2025, the cumulative usage of raised funds amounted to RMB 283,688,338.64, leaving a balance of RMB 559,847,593.49 [1][2]. Fund Management - The company has established a fundraising management system to ensure the effective use of raised funds, adhering to relevant laws and regulations [1]. - A tripartite supervision agreement has been signed with various banks to ensure the proper management of the funds [1][2]. Fund Usage Details - The company has utilized raised funds for specific projects, including: - Special drug and innovative technology research: RMB 6,080,130.83 - Emergency drug network service project: RMB 5,651,013.32 - Factory expansion project: RMB 28,113,571.80 - The total balance in the fundraising account as of June 30, 2025, was RMB 559,847,593.49 after accounting for expenditures and income from financial products [1][2]. Idle Fund Management - The company approved the use of up to RMB 550 million of temporarily idle funds for cash management, with a balance of RMB 490 million invested in structured deposits as of June 30, 2025 [2][5]. - The company has generated income from cash management activities while ensuring that project construction and fund safety are not compromised [2][5]. Surplus Fund Usage - Surplus funds from the completed emergency drug network service project, amounting to RMB 7,851,987.11, will be permanently used to supplement the company's working capital [2][5]. - The company has not encountered any changes in the use of raised funds or any violations in fund management [2][5].

Fundraising Overview - The company raised a total of RMB 500 million through a non-public offering of 79,239,302 shares at RMB 6.31 per share, with a net amount of RMB 486.68 million after deducting underwriting fees and other expenses [1][2] - The funds were deposited into a special account managed by the underwriter, Dongfang Securities [1] Fund Utilization and Balance - As of the reporting date, the net amount of funds utilized was RMB 429.95 million, with an interest income of RMB 0.96 million, resulting in a remaining balance of RMB 47.70 million [2][4] - The company has not encountered any abnormal situations regarding the investment projects funded by the raised capital [4] Fund Management Practices - The company has established a management system for the raised funds, including special account storage and regulatory agreements with banks to ensure proper usage [3][4] - The company has signed four-party and three-party regulatory agreements with banks to clarify the rights and obligations of all parties involved [3] Project Status and Adjustments - The company has extended the timeline for the expected usability of certain projects, including the "Core Component Production Base for Aircraft Seats" and "Seat R&D Center," from December 2024 to December 2025 due to market demand recovery issues [5][6] - There have been no changes in the investment projects funded by the raised capital, and the company has adhered to the original investment plans [4][5]